A Novel Murine GITR Ligand Fusion Protein Induces Antitumor Activity as a Monotherapy that Is Further Enhanced in Combination with an OX40 Agonist

Clinical Cancer Research

Volumn 23, Issue 13, 2017, Pages 3416-3427

  Leyland, Rebecca ^a   Watkins, Amanda ^a   Mulgrew, Kathy A ^b   Holoweckyj, Nicholas ^b   Bamber, Lisa ^a   Tigue, Natalie J ^a   Offer, Emily ^a   Andrews, John ^a   Yan, Li ^b   Mullins, Stefanie ^a   Oberst, Michael D ^b   Ulrichsen, Jane Coates ^a   Leinster, David A ^a   McGlinchey, Kelly ^b   Young, Lesley ^a   Morrow, Michelle ^a   Hammond, Scott A ^b   Mallinder, Philip ^a   Herath, Athula ^a   Ching Leow, Ching ^b   Wilkinson, Robert W ^a   Stewart, Ross ^a   more..

^a MEDIMMUNE LTD   (United Kingdom)

^b MEDIMMUNE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT; CD134 ANTIGEN; CYTOTOXIC T LYMPHOCYTE ANTIGEN 4; GLUCOCORTICOID INDUCED TUMOR NECROSIS FACTOR RECEPTOR; GLUCOCORTICOID INDUCED TUMOR NECROSIS FACTOR RECEPTOR LIGAND FUSION PROTEIN; OX40 LIGAND FUSION PROTEIN; PROGRAMMED DEATH 1 LIGAND 1; PROGRAMMED DEATH 1 RECEPTOR; UNCLASSIFIED DRUG; CD274 PROTEIN, MOUSE; MEMBRANE PROTEIN; ONCOPROTEIN; PDCD1 PROTEIN, MOUSE; TNFRSF18 PROTEIN, MOUSE; TNFSF18 PROTEIN, MOUSE; TNFSF4 PROTEIN, MOUSE; TUMOR NECROSIS FACTOR;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER IMMUNOTHERAPY; CD4+ T LYMPHOCYTE; CD8+ T LYMPHOCYTE; CONTROLLED STUDY; DRUG POTENTIATION; FEMALE; FLOW CYTOMETRY; HEK293T CELL LINE; HUMAN; HUMAN CELL; IN VITRO STUDY; JURKAT CELL LINE; LYMPHOCYTE PROLIFERATION; MALIGNANT NEOPLASM; MONOTHERAPY; MOUSE; NONHUMAN; POLYACRYLAMIDE GEL ELECTROPHORESIS; PRIORITY JOURNAL; REGULATORY T LYMPHOCYTE; TUMOR IMMUNITY; AGONISTS; ANIMAL; ANTAGONISTS AND INHIBITORS; DISEASE MODEL; DRUG EFFECTS; EXPERIMENTAL MELANOMA; GENETICS; IMMUNOLOGY;

ANIMALS; B7-H1 ANTIGEN; CD8-POSITIVE T-LYMPHOCYTES; CTLA-4 ANTIGEN; DISEASE MODELS, ANIMAL; GLUCOCORTICOID-INDUCED TNFR-RELATED PROTEIN; HUMANS; MELANOMA, EXPERIMENTAL; MEMBRANE GLYCOPROTEINS; MICE; ONCOGENE PROTEINS, FUSION; PROGRAMMED CELL DEATH 1 RECEPTOR; TUMOR NECROSIS FACTORS;

EID: 85020629744     PISSN: 10780432     EISSN: 15573265     Source Type: Journal    
DOI: 10.1158/1078-0432.CCR-16-2000     Document Type: Article

References (47)

1. Zou W. Regulatory T cells, tumour immunity and immunotherapy. Nat Rev Immunol 2006;6:295–307.
2. Ronchetti S, Zollo O, Bruscoli S, Agostini M, Bianchini R, Nocentini G, et al. GITR, a member of the TNF receptor superfamily, is costimulatory to mouse T lymphocyte subpopulations. Eur J Immunol 2004;34:613–22.
3. Tone M, Tone Y, Adams E, Yates SF, Frewin MR, Cobbold SP, et al. Mouse glucocorticoid-induced tumor necrosis factor receptor ligand is costimulatory for T cells. Proc Natl Acad Sci U S A 2003;100:15059–64.
4. Ramirez-Montagut T, Chow A, Hirschhorn-Cymerman D, Terwey tH, Kochman AA, Lu S, et al. Glucocorticoid-induced TNF receptor family related gene activation overcomes tolerance/ignorance to melanoma differentiation antigens and enhances antitumor immunity. J Immunol 2006; 176:6434–42.
5. Stephens GL, McHugh RS, Whitters MJ, Young DA, Luxenberg D, Carreno BM, et al. Engagement of glucocorticoid-induced TNFR family-related receptor on effector T cells by its ligand mediates resistance to suppression by CD4tCD25t T cells. J Immunol 2004;173:5008–20.
6. Nishikawa H, Kato T, Hirayama M, Orito Y, Sato E, Harada N, et al. Regulatory T cell-resistant CD8t T cells induced by glucocorticoid-induced tumor necrosis factor receptor signaling. Cancer Res 2008;68:5948–54.
7. Ji HB, Liao G, Faubion WA, Abadia-Molina AC, Cozzo C, Laroux FS, et al. Cutting edge: the natural ligand for glucocorticoid-induced TNF receptor-related protein abrogates regulatory T cell suppression. J Immunol 2004; 172:5823–7.
8. Schaer DA, Budhu S, Liu C, Bryson C, Malandro N, Cohen A, et al. GITR pathway activation abrogates tumor immune suppression through loss of regulatory T cell lineage stability. Cancer Immunol Res 2013;1:320–31.
9. McHugh RS, Shevach EM. the role of suppressor T cells in regulation of immune responses. J Allergy Clin Immunol 2002;110:693–702.
10. Shimizu J, Yamazaki S, Takahashi T, Ishida Y, Sakaguchi S. Stimulation of CD25(t)CD4(t) regulatory T cells through GITR breaks immunological self-tolerance. Nat Immunol 2002;3:135–42.
11. Ko K, Yamazaki S, Nakamura K, Nishioka T, Hirota K, Yamaguchi T, et al. Treatment of advanced tumors with agonistic anti-GITR mAb and its effects on tumor-infiltrating Foxp3tCD25tCD4t regulatory T cells. J Exp Med 2005;202:885–91.
12. Zhou P, L'Italien L, Hodges D, Schebye XM. Pivotal roles of CD4t effector T cells in mediating agonistic anti-GITR mAb-induced-immune activation and tumor immunity in CT26 tumors. J Immunol 2007;179: 7365–75.
13. Liu Z, Tian S, Falo LDJr, Sakaguchi S, You Z. therapeutic immunity by adoptive tumor-primed CD4(t) T-cell transfer in combination with in vivo GITR ligation. Mol ther 2009;17:1274–81.
14. Cohen AD, Schaer DA, Liu C, Li Y, Hirschhorn-Cymmerman D, Kim SC, et al. Agonist anti-GITR monoclonal antibody induces melanoma tumor immunity in mice by altering regulatory T cell stability and intra-tumor accumulation. PLoS One 2010;5:e10436.
15. Bulliard Y, Jolicoeur R, Windman M, Rue SM, Ettenberg S, Knee DA, et al. Activating Fc gamma receptors contribute to the antitumor activities of immunoregulatory receptor-targeting antibodies. J Exp Med 2013;210: 1685–93.
16. Clouthier DL, Watts tH. Cell-specific and context-dependent effects of GITR in cancer, autoimmunity, and infection. Cytokine Growth Factor Rev 2014;25:91–106.
17. Zhou Z, Song X, Berezov A, Zhang G, Li Y, Zhang H, et al. Human glucocorticoid-induced TNF receptor ligand regulates its signaling activity through multiple oligomerization states. Proc Natl Acad Sci U S A 2008; 105:5465–70.
18. Zhou Z, Tone Y, Song X, Furuuchi K, Lear JD, Waldmann H, et al. Structural basis for ligand-mediated mouse GITR activation. Proc Natl Acad Sci U S A 2008;105:641–5.
19. Stewart R, Hammond SA, Oberst M, Wilkinson RW. the role of Fc gamma receptors in the activity of immunomodulatory antibodies for cancer. J Immunother Cancer 2014;2:29.
20. Bulliard Y, Jolicoeur R, Zhang J, Dranoff G, Wilson NS, Brogdon JL. OX40 engagement depletes intratumoral Tregs via activating FcgammaRs, leading to antitumor efficacy. Immunol Cell Biol 2014;92:475–80.
21. Clynes RA, Towers TL, Presta LG, Ravetch JV. Inhibitory Fc receptors modulate in vivo cytotoxicity against tumor targets. Nat Med 2000; 6:443–6.
22. Aspeslagh S, Postel-Vinay S, Rusakiewicz S, Soria JC, Zitvogel L, Marabelle A. Rationale for anti-OX40 cancer immunotherapy. Eur J Cancer 2016; 52:50–66.
23. Pearce EL, Mullen AC, Martins GA, Krawczyk CM, Hutchins AS, Zediak VP, et al. Control of effector CD8t T cell function by the transcription factor Eomesodermin. Science 2003;302:1041–3.
24. Stewart R, Morrow M, Hammond SA, Mulgrew K, Marcus D, Poon E, et al. Identification and characterization of MEDI4736, an antagonistic anti-PD-L1 monoclonal antibody. Cancer Immunol Res 2015;3:1052–62.
25. Croft M, Benedict CA, Ware CF. Clinical targeting of the TNF and TNFR superfamilies. Nat Rev Drug Discov 2013;12:147–68.
26. Sugamura K, Ishii N, Weinberg AD. therapeutic targeting of the effector T-cell co-stimulatory molecule OX40. Nat Rev Immunol 2004;4:420–31.
27. Schaer DA, Murphy JT, Wolchok JD. Modulation of GITR for cancer immunotherapy. Curr Opin Immunol 2012;24:217–24.
28. Redmond WL, Weinberg AD. Targeting OX40 and OX40L for the treatment of autoimmunity and cancer. Crit Rev Immunol 2007;27:415–36.
29. Cohen AD, Diab A, Perales MA, Wolchok JD, Rizzuto G, Merghoub T, et al. Agonist anti-GITR antibody enhances vaccine-induced CD8(t) T-cell responses and tumor immunity. Cancer Res 2006;66:4904–12.
30. Coe D, Begom S, Addey C, White M, Dyson J, Chai JG. Depletion of regulatory T cells by anti-GITR mAb as a novel mechanism for cancer immunotherapy. Cancer Immunol Immunother 2010;59:1367–77.
31. Nimmerjahn F, Lux A, Albert H, Woigk M, Lehmann C, Dudziak D, et al. FcgammaRIV deletion reveals its central role for IgG2a and IgG2b activity in vivo. Proc Natl Acad Sci U S A 2010;107:19396–401.
32. Nimmerjahn F, Ravetch JV. Fcgamma receptors as regulators of immune responses. Nat Rev Immunol 2008;8:34–47.
33. van Olffen RW, Koning N, van Gisbergen KP, Wensveen FM, Hoek RM, Boon L, et al. GITR triggering induces expansion of both effector and regulatory CD4t T cells in vivo. J Immunol 2009;182:7490–500.
34. Kim YH, Shin SM, Choi BK, Oh HS, Kim CH, Lee SJ, et al. Authentic GITR signaling fails to induce tumor regression unless Foxp3t regulatory T cells are depleted. J Immunol 2015;195:4721–9.
35. Tanaka C, O'Reilly T, Kovarik JM, Shand N, Hazell K, Judson I, et al. Identifying optimal biologic doses of everolimus (RAD001) in patients with cancer based on the modeling of preclinical and clinical pharmacokinetic and pharmacodynamic data. J Clin Oncol 2008;26: 1596–602.
36. Derendorf H, Meibohm B. Modeling of pharmacokinetic/pharmacodynamic (PK/PD) relationships: concepts and perspectives. Pharm Res 1999;16:176–85.
37. Weinberg AD, Rivera MM, Prell R, Morris A, Ramstad T, Vetto JT, et al. Engagement of the OX-40 receptor in vivo enhances antitumor immunity. J Immunol 2000;164:2160–9.
38. Rogers PR, Song J, Gramaglia I, Killeen N, Croft M. OX40 promotes Bcl-xL and Bcl-2 expression and is essential for long-term survival of CD4 T cells. Immunity 2001;15:445–55.
39. Redmond WL, Ruby CE, Weinberg AD. the role of OX40-mediated co-stimulation in T-cell activation and survival. Crit Rev Immunol 2009;29: 187–201.
40. Gramaglia I, Jember A, Pippig SD, Weinberg AD, Killeen N, Croft M. the OX40 costimulatory receptor determines the development of CD4 memory by regulating primary clonal expansion. J Immunol 2000;165:3043–50.
41. Schaer DA, Hirschhorn-Cymerman D, Wolchok JD. Targeting tumor-necrosis factor receptor pathways for tumor immunotherapy. J Immunother Cancer 2014;2:7.
42. Mosely SI, Prime JE, Sainson RC, Koopmann JO, Wang DY, Greenawalt DM, et al. Rational selection of syngeneic preclinical tumor models for immunotherapeutic drug discovery. Cancer Immunol Res 2017;5:29–41.
43. Rios-Doria J, Durham N, Wetzel L, Rothstein R, Chesebrough J, Holoweckyj N, et al. Doxil synergizes with cancer immunotherapies to enhance antitumor responses in syngeneic mouse models. Neoplasia 2015;17:661–70.
44. Mitsui J, Nishikawa H, Muraoka D, Wang L, Noguchi T, Sato E, et al. Two distinct mechanisms of augmented antitumor activity by modulation of immunostimulatory/inhibitory signals. Clin Cancer Res 2010;16:2781–91.
45. Lu L, Xu X, Zhang B, Zhang R, Ji H, Wang X. Combined PD-1 blockade and GITR triggering induce a potent antitumor immunity in murine cancer models and synergizes with chemotherapeutic drugs. J Transl Med 2014; 12:36.
46. Melero I, Berman DM, Aznar MA, Korman AJ, Perez Gracia JL, Haanen J. Evolving synergistic combinations of targeted immunotherapies to combat cancer. Nat Rev Cancer 2015;15:457–72.
47. Knee DA, Hewes B, Brogdon JL. Rationale for anti-GITR cancer immunotherapy. Eur J Cancer 2016;67:1–10.